Toponostics of invasive ductal breast carcinoma: combination of spatial protein expression imaging and quantitative proteome signature analysis.

Due to enormous advances in quantitative proteomics and in immunohistochemistry (pathology), the two research areas have now reached the state to be successfully interwoven in order to tackle challenges in toponostics and to open tumor-targeted systems pathology approaches. In this study the differential expressions of candidate proteins nucleophosmin, nucleoside diphosphate kinase A/B (NDKA/B), osteoinducive factor (mimecan), and pyru-vate kinase M2 from a quantitative proteome signature for invasive ductal breast cancer were determined by immunohistochemistry on 53 tissue slices from formalin-fixed and paraffin-embedded tumor and control tissue samples from ten patients and fourteen controls. In addition, 87 images from the Human Protein Atlas representing seven tumor and nine normal breast tissue samples were investigated by computer-assisted semi-quantitative density measurements on nucleophosmin, nucleoside diphosphate kinase A/B (NDKA/B), osteoinducive factor (mimecan), pyruvate kinase M2, glyceraldehyde-3-phosphate dehydro-genase (GAP-DH), and mimecan (osteoinductive factor). Both IHC data sets match well to each other and support the quantitative proteome analysis data. Determining spatial distribution of signature protein expressions by protein imaging on morphologically intact tissue samples at the sub-cellular level and, hence, keeping all topological information, presents an added value to quantitative proteome data. Such comprehensive data sets are needed for both, pathway analyses and for "next generation clinical diagnostics" approaches.

[1]  F. Pontén,et al.  The Impact of Tissue Fixatives on Morphology and Antibody-based Protein Profiling in Tissues and Cells , 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[2]  K. Tomer,et al.  MALDI/MS-based epitope mapping of antigens bound to immobilized antibodies , 2002, Molecular biotechnology.

[3]  F. Pontén,et al.  The Human Protein Atlas—a tool for pathology , 2008, The Journal of pathology.

[4]  Welch Bl THE GENERALIZATION OF ‘STUDENT'S’ PROBLEM WHEN SEVERAL DIFFERENT POPULATION VARLANCES ARE INVOLVED , 1947 .

[5]  S. Leung,et al.  Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study , 2008, Breast Cancer Research.

[6]  A. Leong,et al.  Quantitation in immunohistology: fact or fiction? A discussion of variables that influence results. , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[7]  John McCafferty,et al.  Expression profiling by high-throughput immunohistochemistry. , 2004, Journal of immunological methods.

[8]  John W. Tukey,et al.  Exploratory Data Analysis. , 1979 .

[9]  Peter Woollard,et al.  A Community Standard Format for the Representation of Protein Affinity Reagents* , 2009, Molecular & Cellular Proteomics.

[10]  R M Levenson,et al.  Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment II , 2006, Histopathology.

[11]  Walter Schubert,et al.  Topological proteomics, toponomics, MELK-technology. , 2003, Advances in biochemical engineering/biotechnology.

[12]  M. Glocker,et al.  Mass Spectrometric Characterization of Protein Structure Details Refines the Proteome Signature for Invasive Ductal Breast Carcinoma , 2011, Journal of the American Society for Mass Spectrometry.

[13]  Isabelle Salmon,et al.  Requirements for the valid quantification of immunostains on tissue microarray materials using image analysis , 2009, Proteomics.

[14]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.

[15]  Carolina Wählby,et al.  Bright-field microscopy visualization of proteins and protein complexes by in situ proximity ligation with peroxidase detection. , 2010, Clinical chemistry.

[16]  Coralie Apfeldorfer,et al.  Object orientated automated image analysis: quantitative and qualitative estimation of inflammation in mouse lung , 2008, Diagnostic pathology.

[17]  D. Suckau,et al.  Molecular epitope identification by limited proteolysis of an immobilized antigen-antibody complex and mass spectrometric peptide mapping. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[19]  Stephen M Hewitt,et al.  Tissue microarrays enabling high-throughput molecular pathology. , 2007, Current opinion in biotechnology.

[20]  K. Scholich,et al.  Toponomics: studying protein-protein interactions and protein networks in intact tissue. , 2010, Molecular bioSystems.

[21]  Erik K. Malm,et al.  A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics* , 2005, Molecular & Cellular Proteomics.

[22]  Raouf E Nakhleh,et al.  Error reduction in surgical pathology. , 2009, Archives of pathology & laboratory medicine.

[23]  A Novel Mass Spectrometric Epitope Mapping Approach without Immobilization of the Antibody , 2011 .

[24]  Kristina Schwamborn,et al.  Molecular imaging by mass spectrometry — looking beyond classical histology , 2010, Nature Reviews Cancer.

[25]  Hans-Jürgen Thiesen,et al.  Towards a proteome signature for invasive ductal breast carcinoma derived from label-free nanoscale LC-MS protein expression profiling of tumorous and glandular tissue , 2009, Analytical and bioanalytical chemistry.

[26]  Vilppu J Tuominen,et al.  ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 , 2010, Breast Cancer Research.

[27]  Elston Cw Classification and grading of invasive breast carcinoma. , 2005 .

[28]  C. Elston Classification and grading of invasive breast carcinoma. , 2005, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[29]  M. Glocker,et al.  Rheumatoid Arthritis, a Complex Multifactorial Disease: On the Way Toward Individualized Medicine , 2006 .

[30]  Stephen M Hewitt,et al.  Validation of proteomic‐based discovery with tissue microarrays , 2008, Proteomics. Clinical applications.

[31]  L. McDonnell,et al.  Peptide and protein imaging mass spectrometry in cancer research. , 2010, Journal of proteomics.

[32]  Gloria Bueno,et al.  Review of imaging solutions for integrated quantitative immunohistochemistry in the Pathology daily practice. , 2010, Folia histochemica et cytobiologica.

[33]  D. Ross,et al.  Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Kononen,et al.  A high‐throughput strategy for protein profiling in cell microarrays using automated image analysis , 2007, Proteomics.